Trial Profile
A Study to Evaluate the Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Patients with Hepatocellular Carcinoma (HCC) Treated with Sorafenib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 18 Dec 2015 New trial record